New Delhi: The Central Government has prohibited the manufacture, sale and distribution of 16 fixed-dose combination (FDC) drugs across India after expert committees concluded that these medicines lacked therapeutic justification and were not supported by adequate scientific evidence. The decision has come into effect immediately and is aimed at safeguarding public health.
According to a report by Moneycontrol, the banned formulations include a range of antibiotic combinations, pain-relief medicines, skin-treatment products and certain topical and cosmetic formulations that were found to be irrational during regulatory review.
Why the Government Imposed the Ban
The move follows an evaluation by expert panels and regulatory authorities, which determined that the affected drug combinations offered no proven therapeutic benefit when compared with their potential risks. Authorities concluded that continuing to allow these formulations in the market was not in the interest of public health.
The government stated that these fixed-dose combinations lacked sufficient scientific backing and medical rationale, prompting the nationwide prohibition on their manufacture, sale and distribution.
Several Categories of Medicines Affected
The banned list includes medicines used in different therapeutic segments, including antibiotics, antispasmodic drugs, pain-management formulations and certain cosmetic or topical products. Regulators found that many of these combinations did not provide additional clinical advantages and were considered irrational formulations.
Some diabetes-related and pain-relief combinations have also been removed from the market as part of the latest action.
Part of a Broader Crackdown on Irrational Drug Combinations
The latest prohibition is part of the government’s ongoing efforts to eliminate irrational fixed-dose combinations from the pharmaceutical market. Over the years, authorities have repeatedly taken action against such formulations after expert committees found a lack of therapeutic justification and potential risks to patients.
Health regulators have maintained that while fixed-dose combinations can be beneficial in specific medical conditions, products lacking proven efficacy and safety should not remain available for public use.
Immediate Effect Across the Country
With the notification now in force, the manufacture, sale and distribution of the 16 identified fixed-dose combination drugs have been banned throughout India. The action reflects the government’s continued focus on ensuring that medicines available in the market are backed by scientific evidence, therapeutic value and patient safety considerations.